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Abstract
Costs of tobacco-related disease can be useful evidence for important macroeconomic health policy. The 
costs can be enormous given that tobacco-related diseases have major adverse effect on the quality of life 
and productivity of affected individuals. This is the gap in tobacco-related research in Nigeria that this 
paper attempted to fill. This paper provides estimates of economic costs of four active tobacco-related 
diseases in Nigeria. This paper is a hospital-based study which utilized an exploratory survey carried out 
between March to September 2010 to assess and document different components of economic costs of 
tobacco-related diseases within the Ibadan metropolis, South West Nigeria. A structured questionnaire 
form was used to collect data on tobacco smoking behaviour, as well as direct and indirect costs 
associated with outpatient visits and hospitalization. Using the prevalence-based method of the cost of 
illness (COI) approach, the paper estimated that the mean total direct and indirect costs during 
hospitalization period were $3,142 and $2,322.95 for Stroke or Transient Ischemic attack and lung cancer 
respectively while the costs were$ 1,445.24 and $741.43 for COPD and tuberculosis respectively (in term 
of dollars). The paper found that direct andindirect costs were main lypa id  by out of pocket by the victims 
and their respective families. The results further reveal that the high cost of the disease can be 
catastrophic for individuals from poor households. The paper thus concludes that anti-smoking measures 
to avoid tobacco-related diseases can reduce the economic costs of the disease.
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ECONOMIC COST OF TOBACCO-RELATED DISEASES IN NIGERIA
1.1. Introduction
Health capital has great potential for improvement of the return to investment for economic 
growth and development because healthier workers are physically and mentally more energetic 
(Bloom, 2004). A country with a heavy burden of diseases like tobacco-related diseases tends to 
experience a multiplicity of several impediments to economic progress. Tobacco-related disease 
is a major cause of death throughout the world, claiming the lives of an estimated 13,000 persons 
every day and by 2030, it is expected to kill 10 million people per year between ages 35-69 (Chu 
et al, 2009). Smoking tobacco causes over 25 diseases in man. Ten diseases as a result of 
Maligent Neoplasms (Bladder Cancer, Lung Cancer, Leukemia etc.), five diseases from 
cardiovascular diseases (Coronary Heart Diseases, Cerebrovascular diseases, Stroke etc.), ten 
diseases from respiratory diseases and host of others (including Tuberculosis, Hypertension, 
Heart attack, Asthma etc.) (Hsieh, 1996).
Economic costs represent the monetary burden on society of illness and premature death as 
foregone alternative and are measured in terms of direct and indirect cost (Graham, 1992). Issues 
around tobacco-related diseases and economic costs show the relationship between health and 
economics (De Beyer et al, 2003). That is, the consumption of tobacco has an inverse 
relationship between the economic status and its consumers. This is because thehigher the 
consumptionof tobacco the lower the economic, health and living standards of its 
consumers.Tobacco-related diseases have major adverse effect on the quality of life of affected 
individuals and create a largeadverse effect on households, communities and the society as a 
whole. The economic cost or burden of tobacco-related diseases impacted on household directly 
or indirectly. Most of the tobacco-related diseases are terminal and costly. Households seeking 
health care as a result of tobacco-related diseases tends to reduce consumption on other goods 
because of high cost of treating tobacco-related diseases such as consultation cost, hospital cost, 
transport cost and other costs to treat diseases. The implication of this is that,an increase in 
household expenditure on seeking health carewill reduce households’ income which may result 
into poverty and subsequently leads to macroeconomic problems. For instance, Neubauer et al, 
(2006) stated that the direct cost for acute hospital care, inpatient rehabilitation care,ambulatory
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care and prescribed drugs in Germany were €7.5 billion. .The estimated cost of hospitalization 
for acute asthma was between $ 2,820 and $ 4,843 in France (Jane-Cluade, 2005). The economic 
cost in Thailand of direct out-of pocket medical costs and expenditure for treatment were 
368.49m baht for lung cancer, 71714.88million baht for chronic obstructive pulmonary (COPD) 
and 1773.65million baht for Coronary heart diseases (CHD) (Jittrakul et al, 2006).
Besides, the indirect cost of incapacity due to sickness is the loss of production of the sick person 
(who may probably be the bread winner of the family) and the caregivers who forego his/her 
occupation to visit hospital as a result of a sick member. More so, the changes in illness 
perception and the different health care seeking reflect the high opportunity costs of time and the 
low availability of cash households face during the disease episode.For example, Neubauer et al,
(2006) stated that the indirect cost of mortality was €4.7 billion and €8.8 billion for costs due to 
work loss days and early retirement, respectively.
Furthermore, tobacco-related diseases also impact negatively on government budget (Ross et al, 
2007). This is because government spends more to subsidize for health care on cost of drugs and 
consultation. This means that the more government spends to subsidize health care the less it 
spends on the provision of social amenities and capital goods. In the same vein, adult mortality 
has a significant effect on national economies (Laxinarayan et al, 2007). Tobacco-related 
diseases deplete investment in human and physical capital and reduce work performance in 
developing countries. For instance, in 2005, 35 million people were estimated to have died from 
tobacco-related diseases worldwide (more than 60% of all death globally; WHO, 2005). Hence, 
WHO, (2004) stated that most of tobacco-related diseases death occurred in low and middle 
income countries. Tobacco kills 50% of lifetime smokers and half of these deaths occur among 
people in their middle age (35-69years).
In developing countries like Nigeria, many factors have deepened the economic burden of 
tobacco that causes many diseases. For example, The Federal Government of Nigeria welcomed 
tobacco investment and showed an active support for tobacco multinationals which cost US$ 150 
million investment in Nigeria. Not only that, British American Tobacco Nigeria (BAT) was 
granted a concessionary import duty that lasted until the end of 2003 (Adirieje, 2006). For 
instance, in2006, a survey from 11 government- owned hospitals in Lagos State revealed that at 
least two persons die of a tobacco-related disease daily. It also revealed that same year, there
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were 9750 tobacco-related cases reported in these hospitals. Not only that, the Lagos State 
economy lost N2, 847,000,000 to subsidise tobacco-related diseases treatment (Owoeye, 2010). 
In addition, Nigeria lacks baseline information on medical expenditures attributable to smoking 
pattern (Akinroye, 2004).All these factors impact negatively on the economy.
Many studies have estimated the economic cost of tobacco-related diseases in different countries. 
Few of them are (Rahman et al, 2000) for China, (Jha, 2000; Ligthwood, 2003; Harris, 1998) for 
US and United Kingdom; (McGhee et al., 2005) for Hong Kong; (Jittrakul, 2006) for Thailand 
and (John et al, 2009) for India.In Nigeria, fewer studies like Adelekan et al, 1992; Ndom et al, 
1996; Oluwafemi et al, 2003; Aina et al., 2009 were not definite in estimating the expenditures 
on tobacco-related diseases.And also, the mission of government through Millennium 
Development Goals in health, Nigerian Heart Foundation (NHF), Nigerian Tobacco Control 
Alliance (NTCA) is to limit the frequent occur of diseases given the amount of resources 
allocated to that end by the society. Many health care providers (Government and 
Nongovernmental organization -NGOs) plan to evaluate costs and benefit cash flows over the 
short-term. However, it becomes a difficult issue for health care providers to make interventions 
on the prevalence of tobacco-related diseases especially when the amount of the expenditures on 
the diseases cannot be quantified. This makes formulation and implementation of a national 
policy on tobacco difficult.
Chu et al, (2009) stated that cost estimates help to prioritize substance abuse issues, provide 
useful information for targeting programming and identify information gap. Thus, economic 
costs of illnesses are important information for health decisions. There fore, proper estimate of 
expenditures on the tobacco-related diseases can form framework for important macroeconomic 
health policy. This study intends to estimate the economic cost of tobacco-related diseases in 
Nigeria. Arising from these problems are numbers of research questions. What are the actual 
costs derivable from tobacco smoking? What is the estimate of the amount spent on tobacco- 
related diseases in Nigeria? The objective of this paper is to find answers to these research 
questions.
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The paper proceeds as follows. The next section presents a background on tobacco and tobacco 
related disease in Nigeria followed by a brief literature review in section 3. Section 4 presents the 
Methodology and the results are shown in Section 5. The discussion of the results are in Section 
6 while the paper conclude with Section 7
2.1. Background on Tobacco and Tobacco Related Disease in Nigeria
The economic cost of tobacco consumption in Nigeria varies among people of low, middle and 
high-income earnings (Adelekan et al, 1996). The annual per capital consumption of cigarette in 
Nigeria in 1995 was 191 sticks per day. The annual total consumption of cigarettes was 10259 
million sticks The Prevalence of smoking among adults (15 years and older) in 1990 reveals that 
male adults accounted for 18.4% and female adults were 1.7%. In 2001, the prevalence of male 
youths was 23.9% while female youth was 17.0% (Table 1). The prevalence of smoking among 
male senior executives was to 17.4% while for the female counterparts it was 0.02% (Okojie et 
al, 2000).
Table_L_Smoking prevalence in Nigeria
15 years and older Youth Senior Executives
Male 15.4 23.9 17.4
Female 1.7 17 0.02
Overall 8.9 18.1 13.9
Source:FMOH, Global Youth Tobacco Survey Collaborative Group (2002), Okojie et al., (2000)
The Impact of smoking-related diseases, mortality from cancer, respiratory and circulatory 
diseases in Nigeria in 2000 is high. The mortality rate of male age 45 above that contacted 
Trachea, Lung and Bonchus Cancer was 23% with total population 171,000. The mortality rate 
of males aged 45 above that contacted Lip, Oral Cavity and Pharynx Cancer was 65% with total 
population of 460,000 while female recorded 3.0% mortality rate with total population of 
216,000.
3.1 Review of Empirical Issues
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Tobacco is an agriculture product processed from the leaves of plants in the genus Nicotiana. In 
consumption, it most commonly appears in the forms of smoking, chewing, snuffing, or dipping 
tobacco (WHO, 2007).In the literature, tobacco related diseases vary from country to country due 
to different habits for tobacco usage (Peto et al, 2004).Tobacco is responsible for over 25 
diseases in man. Ten of the diseases are malignant Neoplasms (Bladder cancer, lung cancer, 
leukemia etc.); five of them are cardiovascular diseases (coronary heart diseases, 
Cerebrovascular diseases, stroke etc.); ten of them are respiratory diseases and others including 
hypertension heart attack, asthma etc. (Department of Health and Human Services United State, 
2004). Smoking tobacco is acknowledged to be the cause of many diseases, such as lung cancer, 
chronic bronchitis and emphysema, and ischemic heart disease (Hsieh, 1996)
In Nigeria, the current smoking prevalence among pharmacy students at the University of Lagos 
was 5.5% which is lower than the national prevalence rate of 8.9% (Aina et al, 2009).In China 
and India, studies have shown that the prevalence of tobacco related diseases are the incidence of 
pulmonary tuberculosis. (Gajalakshmi et al, 2003). The prevalence of diseases that is attributable 
to smoking in veteran population in the United State had cases of 90% of lung cancers. 
(Harries,1998). In United States 50% cases are attributed to stroke (Howard; 1994). Farley et al, 
(1998)found out that the prevalence Cerebrovascular Heart Disease (CHD) in Germany was 
35%, stroke 28%. That of atherosclerotic diseases was 28%. The incidences of tobacco were 
high: 54% for CHD, 66% for cerebrovascular diseases and 82% for arterial diseases.
In Hong Kong, China, the prevalence of regular smoking among men in 2000 was 22%. This 
was lower than that of mainland China where over 53% of males smoked in 1998 (McGhee et 
al., 2005). According to McGhee et al., (2006) the current peak in the prevalence of cigarette 
smoking in China occurred about 40 years later than in the United States but postdates that in 
Hong Kong by about 20 years.In India, John et al., (2009) found out that prevalence of 
tuberculosis was 18% and 88% of male gender was attributed to this disease.
The channels through which cost of tobacco-related disease may impact on the economy 
interlink - directly or indirectly. It is well-recognized also that health positively influences 
economic wellbeing, growth and wealth. The reverse influence is also well-recognized. 
Countries would certainly be economically better-off in the absence of ill-health (morbidity and
6
mortality) from epidemic diseases, such as tuberculosis, stroke and cardiovascular diseases etc. 
If left unchecked, there will be poor economic performance and poor health especially at 
individual and household levels.
Direct costs are the value of resources (personal healthcare, hospital care, physician’s services 
and drugs) that could be allocated to other uses in the absence of diseases (Graham, 1992). 
Barcelo, (2000) stated that the direct cost include all medical costs such as cost of drugs, 
hospitalization, out-of-pocket, ambulatory, transport cost, laboratory test and all other Medicare 
expenditures. Single et al., (1998) estimated the direct cost of alcohol, tobacco and illicit drug in 
Canada. The direct cost was $18.4 billion in 1992 which represent $649 per capital 2.7% GDP. 
In the same vein, alcohol accounted for approximately $7.52 billion. Barceloet al, (2000) 
estimated direct costs of diabetes mellitus in Latin America to be US $1, 0721 million.
Neubauer et al, (2006) stated that the direct cost for tobacco-related diseases on hospital care, 
inpatient rehabilitation care, ambulatory care and prescribed drugs were €7.5 billion. The annual 
value of direct medical costs and long term care for tobacco-related diseases in Hong Kong was 
US$532 million for active smoking and US$156 million for passive smoking (McGhee et al, 
2006). Leal et al, (2006) estimated the direct costs of cardiovascular disease and coronary heart 
disease in European Union. Health care costs on CVD in EU were estimated to be EU 60 billion 
representing 57% of total health care.
Ross et al, (2007) stated that the total direct cost of inpatient health care caused by smoking in 
Vietnam was at least 1161829 million Vietnamese dollar or ($US77.5 million) in 2005. This 
represent about 0.22% of Vietnam Gross Domestic Product (GDP) and 4.3% of total health care 
expenditure. The majority of these expenses are for COPD treatment ($VN1033541 million or 
$US68.9 million per year), Lung Cancer ($VN78143 million or $US5.2 per year) and Ischaemic 
diseases ($VN50145 million or $US 3.3 million). Government directly financed about 51% of 
these cost. The rest was financed either by household (34%) or by the insurance sector (15%). 
John et al, (2009) stated that direct medical cost of tobacco related diseases in India amounted to 
$907 million for smoked tobacco and $285 million for smokeless tobacco.
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On the part of indirect cost, it is the value of lost output because of cessation or reduction of 
productivity caused by morbidity and mortality. Morbidity costs are wages lost by people who 
are unable to work because of illness and disability and an imputed value for persons too sick to 
perform their usual housekeeping task while mortality costs are the present value of future 
earnings cost by people who die prematurely (Graham, 1992).Barceloet al, (2000) estimated 
indirect costs of diabetes mellitus in Latin America. The study found out that the cost was US 
$5,4496 million
In Germany, the indirect cost of mortality was €4.7 billion and €8.8 billion for costs due to work 
loss days and early retirement (Neubauer et al, 2006). Indirect cost was estimated to cost EU $ 
29 billion. The productivity loss was estimated to cost about $ 24.4 billion (Leal et al, 
2006). According to John et al, (2009) the indirect morbidity cost of tobacco use in India which 
includes the cost of caregivers and value of work loss due to illness amounted to $398 million for 
smoked tobacco and $104 million for smokeless tobacco. The indirect cost of tobacco, illicit 
drug, alcohol and loss of production in Canada were amounted $4.14 billion while a loss to law 
enforcement agencies was amounted to $1.36 billion.
Economic cost can simply mean an opportunity that is sacrificed when a choice is made (Louie, 
2002). Economic cost includes only real resources consumed as a result of decisions made by 
consumers in the marketplace (Ligthwood, 2003). Hence, economic costs are the direct and 
indirect cost. According to Ligthwood et al, (2000) the estimates of the gros.s' healthcare costs of 
smoking (that is, all the expenditures associated with treating diseases attributable to smoking) 
for high-income countries range between 0.10% and 1.1% of gross domestic product (GDP). 
John et al, (2009) stated that the total cost of tobacco use in India amounted to $1.7 billion. 
Tuberculosis accounted for 18% of tobacco-related diseases which cost $311 million.
Neubauer et al, (2006) stated that the total costs attributable to smoking in Germany were €21.0 
billion. The total costs of treating cardiovascular disease cost the EU economy $169 billion (Leal 
et al, 2006). The annual cost of tobacco-related illnesses in Bangladesh was estimated at 50.9 
billion taka, including 5.8 billiontaka for second-hand smoking (WHO, 2007).Lightwood et al.,
(2008) estimated health care expenditure in California and the total cost of all health care 
expenditures were $86 billion in 2004.The annual economic cost of tobacco-related diseases in
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Philippine was estimated at 6 billion USD (includes healthcare and productivity costs) (Baquilod 
et al., 2006).
3.2 Methodological Review
Graham (1992) used prevalence-based approach to estimate diabetes, cardiovascular and 
hypertension costs. Howard (1994) estimated cost of cancer, cardiovascular, cerebrovascular 
diseases in United State of America with cost of illness approach. Barcelo et al, (2000) estimated 
economic costs of diabetes mellitus in Latin America and the Caribbean with a prevalence based 
approach (COI). Lightwood et al, (2003) used cost of illness to estimate cost of cardiovascular in 
United State of America. In the same vein, Jittrakul (2006) used prevalence-based approach to 
estimate cost of lung cancer and other heart diseases in Thailand. Leal et al, (2006) estimated 
cost of cardiovascular among Europeans Union using cost of illness approach.
McGhee et al, (2006) estimated active and passive smoking-attributable mortality, hospital 
admissions, outpatient, emergency and general practitioner visits for adults and children, use of 
nursing homes and domestic help, time lost from work due to illness and premature mortality in 
the productive years with Population Attributable Fraction (PAF). The study calculated the risk 
of taking time off work for a smoker compared with a never smoked and used this together with 
an estimate of smoking prevalence among workers. Chuina et al, (2006) estimated the economic 
costs of malaria with prevalence-based approach (COI) in rural area in Kenya. Sanghamtra
(2007) used Hedonic Pricing Approach to estimate the cost of HIV and AIDs in India.
Cost of illness method gives estimates of amount spent on medical expenses and employment 
compensation that are foregone as a result of illnesses, accidents or premature death (Golan, 
1999). It is useful in highlighting the impact that illness and diseases have on health services and 
societies. Cost of illness study do not account for pain and suffering, the value of lost leisure 
time, or the costs and benefits of preventive measures (Joel, 2006; Lightwood, 2003). Goldman, 
(1996) and Warner et al., (1999) stated that cost of illness employed a variety of methods of 
estimating the different cost components, attributable risk methodology, incidence-based 
approach, prevalence-based approach and the human capital approach.
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The prevalence-based approach is well suited to estimate the magnitude of diseases costs on 
acute or transient conditions. Prevalence-based approach also identifies the costs incurred during 
a given year by persons with a particular illness (Joel, 2006).The prevalence approach values the 
present costs associated with all existing cases of smoking-produced illness (including future lost 
earnings attributable to current deaths) (Rice et al, 1986).The cost of coronary artery disease in 
the UK was estimated by using the number of prevalent cases and aggregated data relating to 
mortality, morbidity and health service utilization. In addition, a societal perspective was 
employed by including both direct and productivity costs (Shearer, 2004). For example, the 
annual cost in Australia, using prevalence-based approach is AS4909 (National Asthma 
Campaign, 2003).The prevalence approach is good for measuring the effectiveness of cost 
control and how well health care expenditure targets are met (Chor, 1997). For example, 
Lightwood, (2003) used Prevalence-based approach to obtain economic cost of cardiovascular 
disease in United State.
Incidence-based approach is suited to estimate the magnitude of diseases cost for long period of 
time. For cost-of-smoking analysis, the incidence approach values all of the future costs 
associated with new cases of smoking-produced disease during the reference year (Hodgson, 
1992). It is useful for analyses of interventions that might interrupt the development of smoking- 
related illness. For example, in Canada, the lifetime cost per patient suffering with multiple 
sclerosis was estimated to be $1, 148 570 (Canadian Burden of Illness Study Group, 1998).
The country costs of smoking related diseases are often done using the Smoking Attributable 
Fraction (SAF). This measures the average proportion of the occurrence of disease attributable to 
smoking. Accurate estimation of the SAF is complicated because it depends on the demographic 
structure, general health, and smoking habits and history of the population, as well as on the 
characteristics of smokers. (Ligthwood et al, 2000). McGhee (2005) applied smoking SAF 
approach to estimate cost of tobacco-related diseases including passive smoking in Hong Kong. 
The study estimated the attributable number of live lost at any age and under 65 years adjusted 
for the labour force participation rate. Average productive years lost was calculated by 
discounting at 35 per annum and monetized the losses by valuing a working year at the median 
wage in 1998. The study valued an attributable death using the value of 1.4 million euro (€), a
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middle estimate worldwide which was used in a European valuation of air pollution related death 
with an exchange rate of €1 to HK$7.2 equivalent to HK$10 million or US$1.3 million.
The results showed that the cost of visits to public primary care outpatient clinics which were 
attributable to active smoking were estimated as $21 million which is 12% of the total cost for 
such clinics in 1998. The cost of attributable visits to accident and emergency department as a 
result of active smoking was $8 million. The attributable cost of private GP consultations due to 
active smoking was $12 million and $32 million for passive smoking. The value of the 
attributable absences from work was $ 11 million for active smoking and $45 million for passive 
smoking.The attributable cost of nursing home care in those over 65 years for disease due to 
active smoking was $117 million while the cost of home-based care was $0.7 million. For 
passive smoking , home-based care cost $0.3 million but the study did not estimate the cost of 
nursing home care for conditions caused by passive smoking.
John et al, (2009) used smoking attributable fraction (SAF), also known as population 
attributable risk, by disease category, rural/urban district, gender, and age to calculate economic 
cost of tobacco use in India. The estimated SAF is then multiplied by each cost measure of 
interest to derive the smoking attributable cost For instance, the product of SAF and total 
inpatient hospitalization expenditures is smoking attributable hospitalization cost; the product of 
SAF and total morbidity cost is smoking attributable morbidity cost. The results showed that the 
SAFs among men ranges from 22.8% for cardiovascular diseases to 43.2% for neoplasms. The 
SAFs among women are up to 22.6% for tuberculosis and 12.6% for neoplasms.
Neubauer et al, (2006) used Smoking Attributable Fraction (SAF) to assess the negative health 
consequences and associated cost of cigarette smoking in Germany in 2003 and to compare them 
with the respective results from 1993. The study derived SAF in three levels of cigarette smoking 
status: current, former and never. The Smoking-attributable years of potential life lost (YPFF) 
were calculated by multiplying the smoking-attributable deaths by age and sex with the 
respective group-specific life expectancy. The smoking-attributable costs of acute hospital care 
and ambulatory visits were estimated by calculating the proportion of smoking-attributable
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hospital days to the total sum of hospital days. Smoking-attributable hospital days were derived 
by applying the SAFs to the hospital days for Germany in 2003 according to age, sex and disease
More so, Gender-specific and age-specific smoking-attributable fractions (SAFs) of hypertension 
were obtained by multiplying the gender-specific and age specific smoking prevalence by the 
relative risk of hypertension. The smoking-attributable costs of early retirement were determined 
by multiplying the smoking-attributable cases of early retirement, according to age and sex, with 
the respective present value of the future net products per employed person, by age and sex.
3.3Analytical Framework
The various channels through which cost of tobacco-related disease may impact on the economy 
are well-discussed in the growing literature on health and economic growth. Figure 3.1 show the 
linkage between tobacco-related diseases and productivity. Tobacco-related diseases diminish 
health which causes absenteeism, early retirement and reduce labour force from mortality. This 
process leads to high dependency ratio and diminish labour productivity that lower GDP and 
deepening poverty (Abegunde, 2006). The costs and the tobacco-related diseases show a positive 
relationship (De Beyer et al., 2003). That is, when tobacco-related diseases increase, economic 
cost and productivity loss increase. Hence, economic implication of increase in cost of tobacco- 
related diseases is the depletion of available manpower for economic development that results to 
economic losses. The interlink in contrast is that, good health improves levels of human capital 
which may in turn, positively affect individual productivity and ultimately affect economic 
growth rates. Workforce productivity is increased by reducing incapacity, disability and 
workdays lost. Finally, good health increases individuals’ economic opportunities and levels of 
education (schooling and training of manpower).
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Fig 3.1 LINKAGES BETWEEN TOBACCO RELATED DISEASES AND PRODUCTIVITY1
Reduced labour force 
from mortality
Absenteeism, 
disability and early 
retirement
Depleted lifetime 
expectations.
Increased social rate 
of time preference
High
dependency
ratio
Diminished
Labour
Productivity
Reduced access to 
factors of 
production
Increased consumptic 
and reduced saving andN 
investment in physical 
capital
May ultimately discourage foreign direct investment in country
Source: Abegunde (2006)
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4.1. Methodology
This study specifically employed prevalence-based method from cost of illness (COI) approach. 
This approach measures the value of resources used (direct cost) or lost (indirect costs) from 
tobacco-related diseases(Rice et al, 1986; John et al, 2009). This method of estimation is 
designed to measure the aggregate economic burden imposed on society attributable to tobacco- 
related diseases.The estimation of the total costs of tobacco-related diseases follows the approach 
of Sauerborn et al, (1996) which is calculated as follows:
1. Direct costs of tobacco-related diseases
x =  T2=o(.Cd +  Cc +  He + Tc +  Sc +  Lc)...................................................... 1
2. Indirect cost of tobacco-related diseases
> X" 0(( /Vli',)/» )................................................................................................2
3. Economic cost tobacco-related diseases
r:'=„(* + o...................................................................................... 3
Where:
X = direct money costs of treating tobacco-related diseases
(\j = costs of drugs
Cc = consultation cost
Hc = hospitalization cost
Tc = transportation cost
Sc = expenses on supplies
Lc = total sum of charges on laboratory test
Y indirect cost
Ts = time cost of the sick person (days forgone in producing) 
w = income
n = number of illness episode 
a = age coefficient
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s = related to the sick individual
This study considered three components of the economic cost (direct, indirect and total cost) of 
tobacco-related diseases as specified in the three equations above. Equation (1) shows the sum of 
direct healthcare expenditures or financial cost for inpatient hospitalization or outpatient visits, 
drugs, transport, laboratory test, supplies and consultation cost. Equation 2 shows the sum of the 
product of income and time cost of the sick personper number of illness episode. Equation 3 
shows the total sum of equation 1 & 2 that is, direct costs and indirect cost.
4.2. DATA: 
4.2.1. Study design and Sampling:
The study is cross-sectional conducted over a period of two months. It uses multi-stage sample 
design. The first stage was the sampling of hospital and the second stage was the sampling of 
patients. Samples of patients at the hospitals were randomly selected for the study. A survey was 
drawn from a randomly selected sample of n = 320 patients in three hospitals (University 
College Teaching Hospital (Ibadan North LGA); Oluyoro Catholic Hospital andJerico Chest 
Care Clinic (Ibadan South LGA)} in Ibadan, Nigeria. Hence, the study used these hospitals as a 
case study.
4.2.2. Description of the Research Instrument:
The patient questionnaire was designed to obtain information on characteristics such as 
demographics, household monthly expenditure, assets, tobacco usage per member, occupation 
and the educational achievement of each patient. General information on lifestyle habits, health. 
The questionnaire was used to obtain information on health-seeking behavior and the cost of 
treatment for tobacco-related disease patient. Questions was asked to ascertain whether the 
respondent had been diagnosed within the previous six months with any of the five tobacco- 
related diseases- ischemic heart disease (IHD), stroke or transient ischemic attack (TIA), oral 
cancer, lung cancer, laryngeal carcinoma, chronic obstructive pulmonary disease (COPD), 
pulmonary tuberculosis and Bronchi’s disease. The questionnaire was developed by the 
researcher, pre-tested and finalized on the basis of the opinions of experts.
The medical officers in the hospitals assisted with the administration of the questionnaires. They 
were assured of confidentiality and the fact that information obtained would be used for research
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purposes only. They also assisted in ensuring that the questionnaire is properly filled and In 
collecting the completed questionnaires. A senior doctor double-checked the questionnaires and 
supervised the medical officers.
Ethical Consideration
Given the nature of the study, the sampling and data collection procedure ensured that there is 
confidentiality of the data collected. Oral consent was got from the respondents after the 
objectives and procedures of the study have been explained to them. Although there was no 
immediate gain in terms of incentives for the participants, they were made to understand that 
their participation in the study will contribute towards future policy making and assist in the 
design of programmes to help the country’s health system on costing of the diseases. The 
respondents were also informed that they could decline to participate in the study.In addition to 
the above procedure, the study obtainedethical clearance from the University of Ibadan, Nigeria 
/University College Hospital Research Ethics Review Committee (Clearance Number = 
UI/EC/10/0191)
5.1. Results
Table 1 shows the characteristics of the respondents. The proportion of males was 82.75% while 
female was 17.25%. The results on marital status shows that the proportion of single was 
16.90%, 70.09% were married, 9.15% were divorced and 3.87% were separated. Public servants 
were 33.45% of respondents. 35.45% of respondent purchase health insurance while 64.68% 
respondents did not buy health insurance. The results on type of tobacco consumed shown that 
large number of respondents consumed more of cigarette with 53.87% while marijuana, snuff 
and cigar accounted for 31.34%, 8.10% and 6.69% respectively.
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Table 1: Characteristics of the respondents
Freq. Percent
Gender
Male 235.00 82.75
Female 49.00 17.25
Marital
single 48.00 16.90
married 199.00 70.07
divorce 26.00 9.15
separated 11.00 3.87
Occupatn (self)
unemployed 6.00 2.11
employed (govt) 95.00 33.45
employed (private) 61.00 21.48
self employed 98.00 34.51
housewife 4.00 1.41
student 20.00 7.04
Purchase health insurance
yes 102.00 35.92
no 182.00 64.08
Type of tobacco consumption
cigarette 153.00 53.87
cigar 19.00 6.69
snuff 23.00 8.10
marijuana 89.00 31.34
Currently smoking
yes 90.00 31.69
no 194.00 68.31
Educational attainment
none 10.00 3.52
primary 58.00 20.42
secondary 87.00 30.63
post secondary 129.00 45.42
perception of personal health status
good 3.00 1.06
fair 257.00 90.49
bad 24.00 8.45
Other smokers in the residence
yes 119.00 41.90
no 165.00 58.10
Illness classified as
terminal
yes 58.00 20.42
no 226.00 79.58
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The proportion of respondents who were not currently smoking was 68.31% while the proportion 
of respondents who currently smoke was 31.69%. The results on educational attainments showed 
that respondents withpost-secondary education had the highest visit to the three hospitals. This 
proportion was45.42% while 3.3% of respondents without education got the lowest case of 
hospital visit in the three hospitals. This result implies that Medicare and healthcare facilities 
were more crucial to the elite than the illiterate. The result on health status showed that across the 
three hospitals, 90.46% respondents got a fair health status while8.45% got bad health status and 
1.06% got good health status. On terminality of diseases among respondents in the three 
hospitals, a proportion of 79.56% showed that there tobacco-related diseases were not terminal 
(tuberculosis)while 20.42% were tenninal. This means that 20 percent of the respondents are 
suffering from lung cancer and stroke which are tenninal diseases.
The Economic Costs of Tobacco Use
Table 2, shows the components of outpatient cost on four tobacco-related diseases in three 
hospitals in Oyo State, Nigeria. The results are analyzed by diseases and separately for outpatient 
costs. The average total outpatient visit cost of treating stroke or Transient Ischemic Attack 
(TIA) was N22,364.00 while lung cancer, Chronic Obstmctive Pulmonary Diseases (COPD), 
tuberculosis were N17, 265.98, N10,820,00 and 147,505.80 respectively. The stroke of Transient 
Ischemic Attack (TIA) disease bore the highest cost of consultation, dmgs and laboratory test 
which amounted to N816.00; N12,474.00 and N4,240.00 respectively. The outpatient visit costs 
of drugs of stroke or Transient Ischemic Attack (TIA) diseases were more than six times from 
tuberculosis which had the lowest costs amount to 141,266.81.
Table 2: Components of Outpatient Costs (naira)
Consultation Transport Drugs Laboratory
tests
Others TOTAL
stroke or Transient 
ischemic attack (TIA 816.00 1,608.00 12,472.00 4,240.00 3,228.00 22,364.00
lung cancer
785.66 1,271.31 7,927.05 3,581.15 3,700.82 17,265.98
chronic obstructive 
pulmonary diseases 720.00 900.00 5,200.00 2,300.00 1,700.00 10,820.00
(COPD)
tuberculosis
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745.38 861.68 1,266.81 2,286.55 2,345.38 7,505.80
Table 3 shows the components of hospitalization costs. In the table, types of tobacco diseases 
were analyzed by hospitalization costs of bed, feeding and others. The average cost of 
hospitalization for ischemic heart disease was 14126,484.60, stroke or Transient Ischemic Attack 
(TIA) was 14164,472.00, lung cancer was 14156,501.60, Chronic Obstructive Pulmonary 
Diseases (COPD) was 1497,440.00 and tuberculosis was 1442,829.41. Stroke or Transient 
Ischemic Attack (TIA) bore the highest hospitalization cost of bed and feeding which amounted 
to 1440,320.00 and 1433,768.00 respectively. Tuberculosis diseases bore the lowest 
hospitalization cost of bed and feeding which accounted for 1413,888.24 and 148,558.82. The 
reason for the low level of hospitalization of tuberculosis disease is that tuberculosis disease is 
infectious. Therefore, patients with tuberculosis were not allowed for admission into most 
hospitals where this study was conducted.
Table 3: Components of Hospitalization Costs
Bed Feeding Others mean costs of 
hospitalisation
ischemic heart 126,484.60
disease (IHD) 31,500.00 30,369.23 64,615.38
stroke or Transient 164,472.00
ischemic attack 40,320.00 33,768.00 90,384.00
(TIA
lung cancer 156,501.60
38,454.10 31,964.75 86,082.79
chronic obstructive 97,440.00
pulmonary diseases 25,200.00 13,440.00 58,800.00
(COPD)
tuberculosis 42,829.41
13,888.24 8,558.82 20,382.35
Table 4 shows cost of tobacco related diseases by smoking characteristics. The results were 
analyzed by type of tobacco use for types of tobacco related diseases and separated for average 
cost of hospitalization, average cost of outpatient visit, indirect costs and total cost. Stroke or
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Transient Ischemic Attack (TIA ) bore the highest average cost of hospitalization, average cost of 
outpatient visit, indirect cost and average total cost for smokeless and smoked tobacco use where 
smokeless tobacco use wasM215,250.00, 1426,475.00, Ml 13,666.00 and 14355,391.70 while 
smoked tobacco use was 14160.056.00,1422,006.52, 80,14185.51 and 14262,248.60 respectively.
Table 4: Cost of Tobacco Related Diseases by Smoking Characteristics (naira)
mean costs of Mean Mean indirect Mean
hospitalisation Outpatient cost costs Total costs
Ischemic heart disease
(IHD)
smokeless tobacco
162,750.00 16,810.00 26,750.00 206,310.00
smoked tobacco
119,890.90 18,059.09 31,824.24 169,774.30
Stroke or Transient
Ischemic attack
smokeless tobacco
215,250.00 26,475.00 113,666.70 355,391.70
smoked tobacco
160,056.50 22,006.52 80,185.51 262,248.60
Lung cancer
smokeless tobacco
135,520.00 15,053.33 28,151.11 178,724.40
smoked tobacco
159,443.00 17,576.17 58,829.28 235,848.40
COPD
smokeless tobacco
96,600.00 8,200.00 33,400.00 138,200.00
smoked tobacco 98,000.00 12,566.67 22,666.67 133,233.30
Tuberculosis
smokeless tobacco
47,250.00 5,175.00 24,000.00 76,425.00
smoked tobacco
42,753.85 7,545.64 15,288.32 65,587.80
The cost bore by Ischemic Heart Diseases (IHD) was a little higher than lung cancer where 
average cost of hospitalization, outpatient visit, indirect and average total cost for smokeless 
tobacco use was!4162,750.00,1416,810.00,1426,750.00 and 14206,310.00 while that for smoked 
tobacco use was!4199,890.90, 1418,059.09, M31,824.24 and M169,774.30 respectively.
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Tuberculosis disease has the lowest average economic cost of treating tobacco related diseases. 
The average cost of treating tuberculosis for the smokeless tobacco use was greater than that for 
smoked tobacco uses except for the average indirect cost for the smoked tobacco use which 
wasN7,545.64 was greater than the smokeless tobacco use which was$45,175.00
Table 5 shows the cost of tobacco-related diseases by gender. The results were analyzed by type 
of tobacco use by gender separately for average costs of hospitalization, outpatient visit cost, 
indirect cost and average total cost. The respective average cost of hospitalization, outpatient 
cost, indirect cost, and average total cost for males were $4106,126.00, $413,533.02, $441,827.09 
and $4161,486.10 while these for females were $4112,114.30, $413,568.37, $427,231.29 and 
$4152,913.90 respectively. The female average cost of hospitalization and outpatient cost for the 
smoked tobacco use were $4107,887.50 and $413,442.50 while for the corresponding male 
smoked tobacco use were $4104,258.80 and $413,431.18.
Table 5: Cost of Tobacco Related Diseases by Gender (naira)
mean costs of 
hospitalisation
Mean
Outpatient
cost
Mean
indirect
costs
Mean 
Total costs
Male
respondents
smokeless
135,600.00 15,140.71 38,826.19 189,566.90
smoked
104,258.80 13,431.18 42,017.20 159,707.20
Female
smokeless
130,900.00 14,127.78 30,481.48 175,509.30
smoked
107,887.50 13,442.50 26,500.00 147,830.00
All male
106,126.00 13,533.02 41,827.09 161,486.10
All female
112,114.30 13,568.37 27,231.29 152,913.90
Table 6 shows the average costs of tobacco-related disease per person. The result showed the 
analysis of average cost of tobacco-related diseases per person by type of tobacco use. The 
average total cost for smokeless tobacco per person was$4184,066.10 while that for smoked 
tobacco use per person was$4157,886.90 where the average economic cost for tobacco use
21
wasN160,007.10. The average cost of tobacco related diseases per person was higher for all 
smokeless except the average indirect cost for smoked tobacco use which wasN39,639.08.
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Table 6: Average per person cost of Tobacco related Diseases (naira)
mean costs of 
hospitalisation
Mean
Outpatient
cost
Mean
indirect
costs
Mean 
Total costs
All smokeless 133,760.90 14,744.35 35,560.87 184,066.10
respondents
All smoke
respondents 104,814.90 13,432.91 39,639.08 157,886.90
Mean (all
respondents) 107,159.20 13,539.12 39,308.80 160,007.10
Discussion of the Results
This paper presents estimates of the economic cost of tobacco related diseases in Nigeria using. 
The total economic cost of tobacco related diseases by type of tobacco use were Ml,821743.5 
million. The percentage share of total hospitalization cost was for 67.9% from the total economic
Components of costs of tobacco related diseases in Nigeria
Stroke or Transient Lung cancer COPD Tuberculosis ALL
Ischemic attack
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cost while the total outpatient visit cost and indirect costs accounted for 8.2% and 23.9% 
respectively.
The economic cost of tobacco use in Nigeria among gender is important. The average total 
economic cost of male which includes (average hospitalization cost, average outpatient visit cost 
and indirect cost) for type of tobacco use (smokeless and smoked) wasN349,274.1 while that for 
female wasN323,339.26. Not only that, the percentage share of average total economic costs of 
tobacco-related diseases borne by male was 52% while the corresponding female was 47.9%. 
The implication of this result was that males bore higher cost of treating tobacco-related diseases 
than females. Therefore, the burdenof tobacco-related diseases was higher on male than female.
Smokeless tobacco in this study was attributable to “Snuff’ as type of tobacco that is not 
smoked. This is because it is chewed or dousedthroughthe nose. In table 4, Stroke or Transient 
Ischemic Attack (TIA) and Ischemic Heart Disease (IHD) for smokeless had higher cost of 
treatment for tobacco-related illness. The total economic costs borne by smokeless tobacco use 
per person wasN184,066.10 while that for smoked tobacco use wasN157886.90. These results 
showed that the total economic cost of tobacco-related diseases per person was higher for 
smokeless tobacco uses than the smoked tobacco uses in this connection, stroke or Transient 
Ischemic Attack (TIA) and Ischemic Heart Disease (IHD) had the higher share of the cost.
Treating of tobacco-related diseases in Nigeria is costly. More than 76% of the health care cost 
in this study was for hospitalization and outpatient visit expenditures. Given that consumption in 
Nigeria is more prevalent among the poor (Aina, 2009), it is likely that much of the tobacco- 
related diseases and associated economic cost would be higher among them. However, 
hospitalization and cost of outpatient visit for tobacco related diseases force poor people into 
debt traps and can result in severe impoverishment.
Therefore, there are tendencies that the individual seeking healthcare may borrow and sell his/her 
properties during hospitalization or outpatient visit to cover their costs of illnesses. The 
implication of this is that household seeking healthcare may shift expenditures on food, 
education and other household needs. Hence, high economic cost with higher healthcare burden 
of treating tobacco-related diseases can push the sufferers and his/her household into a vicious 
circle of poverty.
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In the same vein, considering the indirect cost, the percentage shares of cost of indirect cost of 
tobacco-related diseases for males was 60%. The loss of production has adverse effects and 
consequent toll on household income and the economy since the indirect costs were higher for 
male who take active parts in production. One of the limitations to this study was that our 
estimates were probably low. This is because of the sample sizes the study adopted and the 
numbers of hospitals visited were limited. However, the estimates presented here are still 
important because it provides insights into the characteristics of tobacco-related diseases in 
Nigeria.
Conclusion and Policy Implications
This study has shown the characteristics of economic costs associated with tobacco-related 
diseases. The study showed that the economic burden of tobacco related diseases was higher 
among the poor and the prevalence of male showed that males’ have higher economic costs than 
the females. Stroke or Transient Ischemic Attack (TIA) had the highest average cost of 
hospitalization, average cost of outpatient visit, indirect cost and average total cost for smokeless 
and smoked tobacco use while the cost of Ischemic Heart Diseases (IHD) was a little higher than 
lung cancer. Tuberculosis diseases bore the lowest hospitalization cost of bed and feeding. These 
findings should give a strong boost to the Nigerian Heart Foundation (NHF), Nigerian Tobacco 
Control Alliance (NTCA) and government to promote tobacco control. Nongovernmental 
organizations should collaborate with government on making policies on health insurance that 
will reduce the social cost and the burden of the costs on personal income of patients.
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